Covance Clinical Research Unit Ltd
Leeds, LS2 9LH, United Kingdom
NCT Number: NCT03046589
Primary Objectives:
1. To determine the safety and tolerability of single and multiple oral doses of DP13 in healthy male subjects 2. To assess the pharmacodynamics of single and multiple ascending oral doses as well as dosing regimen of DP13 on suppression of serum aldosterone in healthy male subjects
Secondary Objectives:
1. To determine the single and multiple oral dose pharmacokinetics of DP13 in healthy male subjects 2. To determine the dose-dependent pharmacodynamic selectivity of DP13 in healthy male subjects
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Leeds, LS2 9LH, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
dose escalation
control to dose-escalation
Time frame: Up to 2 weeks after dosing
Clinical signs and symptoms incl ECG, vital signs, electrolytes
Time frame: Up to 48 hours after dosing
Serum aldosterone concentration
Time frame: up to 48 hours after dosing
Plasma DP13 concentration
Time frame: Up to 48 hours after dosing
Plasma hormone concentrations
Damian Pharma AG
Industry
A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of DP13 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06331884
Healthy Volunteers, Safety and Tolerability
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT01226316
AKT1, Adnexal Diseases
Los Angeles, California, United States
View Trial DetailsNCT06453824
Safety and Tolerability
Miami, Florida, United States
View Trial DetailsNCT06181760
Safety and Tolerability
Randwick, New South Wales, Australia
View Trial Details